Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)

Market Cap	12.09B +1.2%
Revenue (ttm)	3.78B +6.2%
Net Income	799.61M +18.3%
EPS	1.40 +16.6%
Shares Out	563.16M
PE Ratio	15.31
Forward PE	15.46
Dividend	0.90 (4.19%)
Ex-Dividend Date	Jun 20, 2025

Volume	5,809,429
Average Volume	7,710,026
Open	21.65
Previous Close	21.47
Day's Range	21.42 - 21.79
52-Week Range	19.83 - 24.94
Beta	0.18
RSI	46.27
Earnings Date	Apr 28, 2026

About SHA:600285

Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 2,435
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600285

Financial Performance

In 2024, SHA:600285's revenue was 3.50 billion, an increase of 5.72% compared to the previous year's 3.31 billion. Earnings were 722.55 million, an increase of 27.19%.